Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2026)

Argenx Se's (ARGX) quarterly Liabilities and Shareholders Equity came in at $10.0 billion in Q2 2026, up 39.81% YoY from $7.2 billion in Q2 2025, and up 15.54% on a QoQ basis from $8.7 billion in Q4 2025.

Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

Argenx Se (ARGX) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $10.0 billion in Q2 2026.

  • Quarterly Liabilities and Shareholders Equity rose 39.81% year-over-year to $10.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.7 billion (up 39.89% YoY) and the FY2025 annual result came in at $8.7 billion, up 39.99% from the prior year.
  • Liabilities and Shareholders Equity grew to $10.0 billion in Q2 2026, from $8.7 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $10.0 billion in Q2 2026 to a low of $3.1 billion in Q4 2022.
  • A 5-year average of $5.7 billion and a median of $4.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity decreased 1.71% — and 2024, when it surged 50.18%.
  • Tracing ARGX's Liabilities and Shareholders Equity over 5 years: stood at $3.1 billion in 2022, then surged by 44.93% to $4.5 billion in 2023, then soared by 36.55% to $6.2 billion in 2024, then surged by 39.99% to $8.7 billion in 2025, then rose by 15.54% to $10.0 billion in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $10.0 billion (Q2 2026), $8.7 billion (Q4 2025), and $7.2 billion (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn 5.31 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 10.03 Bn
Dec 31, 2025 8.68 Bn
Jun 30, 2025 7.18 Bn
Dec 31, 2024 6.20 Bn
Jun 30, 2024 4.80 Bn
Dec 31, 2023 4.54 Bn
Jun 30, 2023 3.19 Bn
Dec 31, 2022 3.13 Bn
Jun 30, 2022 3.25 Bn
Dec 31, 2021 2.85 Bn
Jun 30, 2021 3.21 Bn
Dec 31, 2020 2.21 Bn
Jun 30, 2020 2.23 Bn
Dec 31, 2019 1.59 Bn
Jun 30, 2019 1.13 Bn
Dec 31, 2018 660.25 Mn
Jun 30, 2018 429.66 Mn
Dec 31, 2017 436.72 Mn
Jun 30, 2017 203.95 Mn
Dec 31, 2016 114.20 Mn